NICE Guidelines

The National Institute for Health and Clinical Excellence [NICE]
NICE Guidelines for Diabetes

NICE is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health. NHS Guidelines advise the NHS on caring for people with specific conditions or disease and the treatments they should receive. In England and Wales, the NHS should follow our recommendations. Therefore local Primary Care Trusts [PCTs] should follow NICE Guidance but they are not obliged to do so. If you are not receiving the care that NICE recommends, then you can enquire why not.

If you want to find out what care and treatment you should be receiving, you can access the full guidance, a summary of the guidance or a version written for the general public [non-medical people] from their website: www.nice.org.uk . For people who do not have access to the internet, copies of the guidance can be obtained by phone: 0845 003 7783.

Here are the NICE Guidelines related to diabetes:

Insulin Pump Therapy
http://www.nice.org.uk/Guidance/TA151

Diabetes (Type 1 & 2) – Patient Education Models
http://www.nice.org.uk/guidance/ng17

Diabetes (Type 1 & 2) – Inhaled Insulin
http://www.nice.org.uk/Guidance/TA113

Medicines  Adherence
https://www.nice.org.uk/Guidance/CG76

Type 1
http://www.nice.org.uk/guidance/ng17
http://www.nice.org.uk/guidance/ng18
http://www.nice.org.uk/guidance/ng19

Type 2
http://www.nice.org.uk/guidance/ng28

Diabetes (Type 1 & 2) – Long acting insulin analogues
http://www.nice.org.uk/guidance/ng17

Diabetes in pregnancy
http://www.nice.org.uk/guidance/ng3

Management of long-term sickness and incapacity for work
http://www.nice.org.uk/Guidance/PH19

Public Health Guidance on Physical Activity
https://www.nice.org.uk/guidance/ph8 – Physical Activity and the environment
https://www.nice.org.uk/guidance/ph35 – Type 2 diabetes prevention

Type 2 – Footcare
http://www.nice.org.uk/guidance/ng19

Type 2 – Bydureon Draft Guidance
http://www.nice.org.uk/newsroom/pressreleases/LongActingExenatideForType2Diabetes.jsp